Q-omics provides the consensus-scored SLC22A18AS profile across patient tissues and cancer cell-line models. SLC22A18AS expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SLC22A18AS is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, SLC22A18AS RNA expression shows 14,544 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, COAD, and TGCT as cancer lineages where SLC22A18AS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC22A18AS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC22A18AS survival associations across molecular data types. SLC22A18AS RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC22A18AS RNA expression–survival associations across cancer types. High SLC22A18AS expression shows unfavorable associations in LAML, ACC, HNSC and PAAD, but favorable associations in KIRP and MESO. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for SLC22A18AS RNA expression.
This table summarizes SLC22A18AS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SLC22A18AS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC22A18AS shows lower tumor expression in COAD, KICH and READ and higher tumor expression in HNSC, LUAD and THCA. The COAD box plot shows higher SLC22A18AS RNA expression in normal versus tumor tissue (log2 FC = −2.254, t-test p < 0.001).
This table shows molecular features associated with SLC22A18AS in patient tissues and cancer cell lines. In patient samples, SLC22A18AS shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC22A18AS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
